<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172195</url>
  </required_header>
  <id_info>
    <org_study_id>1708033</org_study_id>
    <secondary_id>ANSM</secondary_id>
    <nct_id>NCT03172195</nct_id>
  </id_info>
  <brief_title>Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up</brief_title>
  <official_title>Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flare-up of ulcerative colitis (UC) is characterized by the inflammation of colon mucosa that
      requires the use of immunosuppressive therapies. In previous studies, the active role of
      cytomegalovirus (CMV) has been demonstrated, with a correlation between the cytomegalovirus
      DNA ((deoxyribonucleic acid) load in the inflamed tissue and the resistance to successive
      lines of immunosuppressive therapy (Roblin et al., Am J Gastroenterol 2011). The main aim of
      this monocentric prospective study is to evaluate the DNA viral load by qPCR (Polymerase
      Chain Reaction) of 3 herpesviruses (Epstein-Barr virus, herpes virus 6 and herpes simplex)
      together with that of CMV in colonic mucosa depending of the local inflammation
      (endoscopically normal region, inflamed mucosa or ulcer) in patients suffering of moderate to
      severe UC flare-up (Mayo score &gt;6 with endoscopic score higher or equal than 2). The viral
      load will also be correlated to the Mayo endoscopic score and the response to
      immunosuppressive drugs (steroid and anti-TNF (Tumor Necrosis Factor) monoclonal antibodies).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with different viral load in the colonic mucosa</measure>
    <time_frame>day 1</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.
It will be measured by Polymerase Chain Reaction technical in colonic mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of the different viral loads with the Mayo endoscopic score</measure>
    <time_frame>Day 1</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.
It will be measured by Polymerase Chain Reaction technical in colonic mucosa The Mayo endoscopic score integrate the severity from lesions of colonic mucosa measured by rectosigmoidoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the different viral loads with the steroid treatment response</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.
It will be measured by Polymerase Chain Reaction technical in colonic mucosa.
Steroid treatment response is defined by clinic mayo score &lt; 3 measured by rectosigmoidoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the different viral loads with the anti-TNF treatment response</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Different viral loads are a composite outcome : viral load of CMV, EBV, HHV-6 and HSV.
It will be measured by Polymerase Chain Reaction technical in colonic mucosa. anti-TNF treatment response is defined by clinic mayo score &lt; 3 measured by rectosigmoidoscopy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ulcerative colitis will have a rectosigmoidoscopy, biopsies and blood sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>rectosigmoidoscopy</intervention_name>
    <description>A rectosigmoidoscopy will be realized and two fragments will be collected.</description>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biopsies</intervention_name>
    <description>For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.</description>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Blood sample will be collected in more.</description>
    <arm_group_label>Patients with ulcerative colitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18 years

          -  Voluntary to participate to the study

          -  Flare-up of ulcerative colitis with Mayo score &gt;6

          -  Ability to receive steroid or anti-TNF therapy

          -  Agree the rectosigmoidoscopy and the therapies

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Pregnancy

          -  Disagree the rectosigmoidoscopy or the therapies

          -  Participation to the evaluation of a new therapy

          -  Colectomy (partial or total)

          -  Contraindication of steroid or anti-TNF therapy

          -  Anticoagulant drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Roblin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>inflammation</keyword>
  <keyword>immunosuppressive drugs</keyword>
  <keyword>herpesvirus</keyword>
  <keyword>qPCR</keyword>
  <keyword>colonic mucosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

